- Home
- IP vs RPRX Comparison
IP vs RPRX Comparison
Compare IP & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IP | RPRX |
|---|---|---|
| Founded | 1898 | 1996 |
| Country | United States | United States |
| Employees | 62602 | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8B | 19.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | IP | RPRX |
|---|---|---|
| Price | $33.43 | $49.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $45.67 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 6.5M | 2.5M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.44% | 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $7.98 | $38.63 |
| Revenue Next Year | $3.53 | $4.73 |
| P/E Ratio | ★ N/A | $27.88 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $30.70 | $31.97 |
| 52 Week High | $56.13 | $50.25 |
Technical Indicators
Market Signals| Indicator | IP | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 60.63 |
| Support Level | N/A | $35.34 |
| Resistance Level | $39.52 | $50.08 |
| Average True Range (ATR) | 1.32 | 0.86 |
| MACD | -0.13 | -0.04 |
| Stochastic Oscillator | 36.21 | 68.45 |
Price Performance
Historical ComparisonAbout IP International Paper Company
International Paper manufactures packaging products and cellulose fibers. It accounts for roughly one-third of the North American corrugated packaging market. The company also has a substantial presence in Europe following its acquisition of DS Smith. International Paper serves a variety of end markets, including industrial, consumer products, and manufacturing.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.